Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah B Miller

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Cancer Research|October 26, 2018
The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line PanelAnne Monks, Yingdong Zhao, Curtis Hose, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2025
A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid TumorsSarah J Shin, Geraldine O'Sullivan Coyne, Shivaani Kummar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2021
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid TumorsNaoko Takebe, Abdul Rafeh Naqash, Geraldine O'Sullivan Coyne, et al.
Cancer Chemotherapy and Pharmacology|April 22, 2020
Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumorsGeraldine O 'Sullivan Coyne, Lihua Wang, Jennifer Zlott, et al.
Cancer Research|November 17, 2019
Clinical Evolution of Epithelial-Mesenchymal Transition in Human CarcinomasTony Navas, Robert J Kinders, Scott M Lawrence, et al.
Cancer Chemotherapy and Pharmacology|December 22, 2025
A phase 1 study of orally administered 5-fluoro-2'-deoxycytidine with tetrahydrouridine in patients with refractory solid tumorsAlice P Chen, Shivaani Kummar, Larry Rubinstein, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Cancer Research|October 26, 2018
The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line PanelAnne Monks, Yingdong Zhao, Curtis Hose, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2025
A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid TumorsSarah J Shin, Geraldine O'Sullivan Coyne, Shivaani Kummar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2021
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid TumorsNaoko Takebe, Abdul Rafeh Naqash, Geraldine O'Sullivan Coyne, et al.
Cancer Chemotherapy and Pharmacology|April 22, 2020
Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumorsGeraldine O 'Sullivan Coyne, Lihua Wang, Jennifer Zlott, et al.
Cancer Research|November 17, 2019
Clinical Evolution of Epithelial-Mesenchymal Transition in Human CarcinomasTony Navas, Robert J Kinders, Scott M Lawrence, et al.
Cancer Chemotherapy and Pharmacology|December 22, 2025
A phase 1 study of orally administered 5-fluoro-2'-deoxycytidine with tetrahydrouridine in patients with refractory solid tumorsAlice P Chen, Shivaani Kummar, Larry Rubinstein, et al.
Pageof 2